SCHEMBL1703078

SCHEMBL1703078

CCN(CC)CCn1cc(N)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
LMNA P02545 3/20 0.39
ALDH1A1 P00352 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
PKM P14618 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 3/20 0.36
MAPK1 P28482 2/20 0.36
CYP1A2 P05177 1/20 0.36
TNNI3 P19429 1/20 0.36
STAT6 P42226 1/20 0.36
TNNT2 P45379 1/20 0.36
TNNC1 P63316 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RAD52 P43351 1/20 0.34
HDAC4 P56524 1/20 0.33
GRK6 P43250 1/20 0.33
HRH3 Q9Y5N1 3/20 0.33
HRH4 Q9H3N8 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19020399 0.84 MAPT (0.38) MAPTLMNAALDH1A1L3MBTL1PKM
SCHEMBL1703246 0.81 MAPT (0.41) MAPTLMNAALDH1A1L3MBTL1PKM
Hydrochloric Acid SCHEMBL23704668 0.80 MAPT (0.44) MAPTLMNAALDH1A1L3MBTL1PKM
SCHEMBL25843713 0.80 LMNA (0.40) LMNAALDH1A1L3MBTL1PKMKMT2A
SCHEMBL10256261 0.79
SCHEMBL15155092 0.79 ALDH1A1 (0.39) MAPTLMNAALDH1A1L3MBTL1PKM
SCHEMBL23544858 0.77 KDM4E (0.36) ALDH1A1L3MBTL1PKMKMT2APOLB
SCHEMBL23444508 0.76 TAS2R8 (0.42) MAPTLMNAALDH1A1L3MBTL1PKM
SCHEMBL15650950 0.76 L3MBTL1 (0.44) MAPTLMNAALDH1A1L3MBTL1PKM
SCHEMBL671403 0.75 MAPT (0.39) MAPTLMNAALDH1A1L3MBTL1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4656249-A2 PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR Daewoong Pharmaceutical Co., Ltd. (KR) 2025-12-03 EP disclosed
EP-3478687-B1 PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR DAEWOONG PHARMACEUTICAL CO LTD (KR) 2024-03-20 EP disclosed
EP-3950691-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR Daewoong Pharmaceutical Co., Ltd. (KR) 2022-02-09 EP disclosed
CN-109311896-B Pyrazolopyrimidine derivatives as kinase inhibitors 株式会社大熊制药 2021-08-24 CN disclosed
CN-113135920-A Pyrazolopyrimidine derivatives as kinase inhibitors 株式会社大熊制药 2021-07-20 CN disclosed
US-10961247-B2 Pyrazolopyrimidine derivatives as kinase inhibitor DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2021-03-30 US disclosed
US-20200317673-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2020-10-08 US disclosed
CN-110835320-A Diaminopyrimidine compound and application thereof 江苏奥赛康药业有限公司 2020-02-25 CN disclosed
CN-102666545-B As the heterocycle Pyrazolopyrimidine analogs of JAK inhibitor CELLZOME LTD. (GB) 2016-04-06 CN disclosed
US-9242987-B2 Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors CELLZOME LIMITED (GB) 2016-01-26 US disclosed
US-8426408-B2 Pyrimidine inhibitors of kinases ABBVIE INC. (US) 2013-04-23 US disclosed
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2012-10-04 US disclosed
CN-102666545-A Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors CELLZOME LTD 2012-09-12 CN disclosed
EP-2440548-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS Abbott Laboratories (US) 2012-04-18 EP disclosed
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2010-12-16 US disclosed
WO-2010144468-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES AURKA, AURKC, AURKB MAPT 2310/4885LMNA 2413/4885ALDH1A1 899/4885
US-20200317673-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR MAP3K5, MAP3K2, MAPKAPK5 MAPT 2758/4885LMNA 4349/4885ALDH1A1 1963/4885
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS JAK1, JAK3, JAK2 MAPT 4393/4885LMNA 4606/4885ALDH1A1 2233/4885
US-10961247-B2 Pyrazolopyrimidine derivatives as kinase inhibitor MAP3K5, MAP3K2, MAPKAPK5 MAPT 2758/4885LMNA 4349/4885ALDH1A1 1963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.